Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir

Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset, P140, the world’s first “Immunormalizer.” The three discoveries that reset the strategy Under-dosing: The team concluded the dose used in the Phase III trial was far…